The Food and Drug Administration has approved Zerbaxa (ceftolozane/tazobactam), a new antibacterial drug product, to treat adults with complicated intra-abdominal infections and complicated urinary tract infections.
As the evolution of antibiotic resistance in bacteria occurs at an alarming rate, the President’s Council of Advisors on Science and Technology announced that it released to the president last week a report, called "Combating Antiboitic Resistance."
Minnesota Gov. Mark Dayton last week signed a bill that will prohibit the use of the antibacterial ingredient triclosan in consumer hygiene products beginning Jan. 1, 2017, according to an Associated Press report published Monday.
Last week, more than 30 organizations — including the American Medical Association, Infectious Diseases Society of America and Pew Charitable Trusts — urged Congressional leaders to strengthen the labeling requirements for drugs approved under the proposed Antibiotic Development to Advance Patient Treatment Act of 2013 (ADAPT Act) limited population approval pathway, which will streamline regulatory approval for antibiotics.
Minor, uncomplicated wounds, such as the typical cuts and scrapes of childhood, are less likely to become infected when kept clean and moist and treated with topical antibiotics, according to a literature review published online Friday in the Annals of Emergency Medicine, the peer-reviewed scientific journal for the American College of Emergency Physicians.